Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $850.00 price objective on the biopharmaceutical company’s stock. Argus’ target price suggests a potential upside of 12.10% from the company’s previous close.

REGN has been the topic of a number of other reports. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Royal Bank Of Canada reissued a “sector perform” rating and issued a $737.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $804.26.

Regeneron Pharmaceuticals Trading Up 1.0%

Shares of Regeneron Pharmaceuticals stock opened at $758.27 on Thursday. The firm’s 50 day moving average is $785.06 and its 200 day moving average is $720.91. The firm has a market capitalization of $78.07 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the company earned $12.81 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,215 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. The trade was a 8.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,946 shares of company stock valued at $3,302,458 in the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $11,358,000. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. Contravisory Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $6,327,000. Oxbow Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $3,342,000. Finally, Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $323,249,000. Institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides significant financial and pipeline upside. Regeneron will receive $1 billion upfront and could earn up to $7 billion in milestone payments by adding REGN20423, a long-acting IL-13 antibody, an IL-4xIL-13 bispecific, and two additional preclinical antibodies to the collaboration. The companies will share development and commercialization costs and future profits, reducing Regeneron’s financial burden while expanding its immunology pipeline. Sanofi and Regeneron expand global alliance press release
• Positive Sentiment: Weight-loss combination data strengthen Regeneron’s metabolic-disease opportunity. An experimental Regeneron drug reduced muscle loss by 50% when combined with Novo Nordisk’s semaglutide versus semaglutide alone in an obesity study. Preserving muscle mass could help differentiate future therapies, though the asset remains investigational. Regeneron drug muscle-loss study
• Neutral Sentiment: Analyst opinions are mixed. Zacks upgraded REGN to “strong buy,” and broader sell-side coverage reflects a “moderate buy” view. However, Royal Bank of Canada reaffirmed a “sector perform” rating with a $737 price target, below the referenced share price, suggesting limited near-term valuation upside. Royal Bank of Canada Regeneron rating
• Negative Sentiment: Eylea faces increasing competitive pressure. Kodiak Sciences reported Phase 3 results indicating its eye-disease candidates delivered comparable vision outcomes to Eylea with dosing approximately every six months, versus Eylea’s more frequent regimen. If confirmed, longer-lasting alternatives could threaten Regeneron’s ophthalmology revenue and market share. Regeneron eye-disease competition analysis

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.